𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy

✍ Scribed by Koichi Watashi; Kunitada Shimotohno

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
244 KB
Volume
17
Category
Article
ISSN
1052-9276

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Hepatitis C virus (HCV) is a major causative agent of liver diseases such as chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Because the current standard therapy, interferon (IFN) or pegylated‐IFN alone or in combination with ribavirin, is ineffective on approximately half of the HCV‐infected patients, alternative therapeutics are greatly needed. The chemical genetics method is a useful strategy to elucidate molecular mechanisms of the viral life cycle and screen for anti‐viral agents. This review focuses on the use of chemical genetics approach to virology, which could be called ‘chemical virology’, and introduces an example of such analysis. From a cell culture‐based screening, an immunosuppressant cyclosporin A (CsA) was identified as an anti‐HCV compound. Analysis using CsA as a bioprobe showed that cyclophilin (CyP) B, a cellular target of CsA, regulates the function of HCV RNA polymerase NS5B, which is essential for efficient viral genome replication. By targeting CyP, HCV genome replication was drastically suppressed. Thus, chemical genetics analysis identified CyPB as a cellular cofactor of HCV genome replication and a target for novel anti‐HCV agents. Copyright © 2007 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Hepatitis C virus nonstructural protein
Hepatitis C virus nonstructural protein 5A inhibitors: Novel target—Now for new trials and new treatment strategies
✍ Alex J. Thompson; Paul J. Clark; John G. McHutchison 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 365 KB 👁 1 views

The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be approaching 200 million people. Current therapy relies upon a combination of pegylated interferon-alpha and ribavirin, a poorly tolerated regimen typically associated with less than 50% sustained virological res

Prospective assessment of donor blood sc
Prospective assessment of donor blood screening for antibody to hepatitis C virus by first- and second-generation assays as a means of preventing posttransfusion hepatitis
✍ S Takano; K Nakamura; S Kawai; O Yokosuka; Y Satomura; M Omata 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB 👁 1 views

In November 1989, the Japanese Red Cross began transfusion. [4][5][6] In December 1989, first-generation hepscreening blood donors for the hepatitis C virus antiatitis C virus antibodies (anti-HCV) to detect the antibody (anti-HCV) by first-generation assay and high-titer body against nonstructural

Genetic immunization and comprehensive s
Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen
✍ P. Martin; P. Parroche; L. Chatel; C. Barretto; A. Beck; C. Trépo; C. Bain; Y.C. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 1 views

## Abstract Interferon‐γ (IFNγ)‐producing CD8+ T cells have been shown to play a key role in the control or eradication of hepatitis C virus (HCV) infections. In particular, T cells specific of the non‐structural protein 3 (NS3) are often associated with control of viremia. The aim of the study was